- Homepage >
- Innovation >
- Publications
-
12/07/2011 Influence de 24h Restriction de Fluides sur L’humeur et marqueurs physiologiques de l’hydratation chez la femme.
Pross N, Barnouin R, Girard N, Santoro F, Klein A, Guelinckx I, Demazières A, Le Bellego L.
Read more > -
12/07/2011 Quels effets d’une déshydratation sur les fonctions cognitives et le bien être ?
Pross N.
Read more > -
11/24/2011 Comparaison de la variabilité intra- et inter- individuelle des paramètres polysomnographiques, chez des volontaires sains et des patients insomniaques adultes
Cornette F, Lerner C, Metzger D, Pross N, Muzet A, Staner L
OBJECTIFS: Cette étude évalue la variabilité inter- (VAR ir) et intra- (VAR ia) sujets de paramètres sommeil chez des volontaires sains (VS) comparés à des patients insomniaques (PI).
Read more > -
11/24/2011 Comparaison des effets d'une restriction de sommeil chez des volontaires sains et des patients insomniaques adultes : polysomnographie, actigraphie et holter cardiaque
Cornette F, Lerner C, Viardot G, Muzet A, Staner L
OBJECTIFS : Le but de cette étude consiste à comparer des volontaires sains (VS) et des patients insomniaques (PI) au cours d’une restriction de sommeil (RS), au niveau du sommeil (PSG), de l’activité motrice (actigraphie) et de l’activité cardiaque autonome (holter). Read more > -
11/15/2011 Influence of an acute fluid restriction on mood and cognition in women in daily life.
Pross N.
Read more > -
11/12/2011 The novel compound BNC210 partially reduces Panic Symptom Scale scores in a model of CCK-4 induced panic in healthy volunteers.
O'Connor S, Doolin E, Pross N, Metzger D, Guichard N, Andriambeloson E, Kremmidiotis G, Danjou P.
Read more > -
11/02/2011 Oculomotricity does not influence resting gamma eeg activity following a subanesthetic dose of ketamine
Boeijinga P, DanjouP, Otmani S, Monnier A, MetzgerD and Patroneva A
Ketamine a NMDA non-competitive antagonist has been used as a model of psychosis for many years; more recently some preliminary clinical data have suggested a rapid and long lasting antidepressant effect of a single dose of ketamine. In rodents, ketamine has been shown to increase gamma frequency EEG power and produce nystagmus...
Read more > -
10/26/2011 Influence of a 24h Fluid Restriction on Mood and Physiological Markers of Dehydration in Women.
Pross N, Chevillotte E, Barnouin R, Girard N, Santoro F, Klein A, Demazières A, Le Bellego L.
Read more > -
10/03/2011 ERP decomposition techniques to infer functional modules in the human brain: a neurotechnology lesson from cognitive responses and vigilance studies
Boeijinga P., Viardot G., Pross N.
Read more > -
09/13/2011 Use of an adaptative design to adjust for an unknown response rate by sample size readjustment: case of a CCK-induced anxiety model as a POC study.
Danjou P, Pross N, Metzger D, Kremmidiotis G, Doolin L, Wagner S, Vandehende F, O’Connor S.
-Existing POC designs in anxiety disorders.
Read more >
-Preclinical data on BNC210 and model alignment between species.
-Principle of model and historical data for response rate and magnitude of drug response
-Simulations and hypotheses for sample size based on in-house data and literature -
09/04/2011 Hydration and cognitive performance.
Pross N, Demazière A, Barnouin R, Klein A, Le Bellego L.
Read more > -
09/03/2011 Pharmacodynamic effects of single oral doses of the novel anxiolytic compound BNC210 in healthy male volunteers
O'Connor S, Doolin E, Metzger D., Boeijinga P, Pross N, Drutinus E, Andriambeloson E, Kremmidiotis G, Danjou P
BNC210 is a novel agent that exhibits potential utility for the treatment of anxiety and
depression. In preclinical animal models it exhibits anxiolytic and antidepressant effects
without inducing side effects associated with benzodiazepines (BZD) and SSRIs.
A phase I clinical study was conducted at FORENAP Pharma (France) in healthy male
subjects to investigate the potential side effect profile of BNC210 in comparison to Lorazepam, a BZD commonly used in the treatment of anxiety.
Read more > -
09/03/2011 Pharmacodynamic effects of single oral doses of the novel anxiolytic compound BNC210 in healthy male volunteers.
O'Connor S, Doolin E, Metzger D, Boeijinga P, Pross N, Drutinus E, Andriambeloson E, Kremmidiotis G, Danjou P.
Read more > -
09/02/2011 Structured multiplicity and confirmatory statistical analyses in pharmacodynamic studies using the quantitative electroencephalogram
Ferber G, Staner L, Boeijinga P.
Pharmacodynamic (PD) clinical studies are characterised by a high degree of multiplicity. This multiplicity is the result of the design of these studies that typically investigate effects of a number of biomarkers at various doses and multiple time points. Measurements are taken at many or all points... Read more > -
07/16/2011 EEG effects of scopolamine in healthy subjects: a standardized low resolution brain electromagnetic tomography (sLORETA) study.
Soufflet L, Boeijinga P, Pross N, Danjou P, Staner L.
Read more > -
07/01/2011 Effects of a reduced water intake on cognitive performance and mood in women.
Pross N.
Read more > -
06/11/2011 Mood and REM sleep effects of a 6-day 4-h sleep restriction protocol in healthy female subjects.
Cornette F, Pross N, Trecherel C, Gardinier S, Mallet de Chauny E, Metzger D, Guinot C, Muzet A, Morizot F, Staner L.
Read more > -
06/11/2011 Differential sleep EEG effects of sleep restriction versus Temazepam in healthy subjects and patients with psychophysiological insomnia.
Staner L, Cornette F, Pross N, Trecherel C, Girard N, Mallet de Chauny E, Metzger D, Muzet A.
Read more > -
05/31/2011 Multi-array pain model for analgesic testing in healthy subjects.
Danjou P, Goupil N, Mallet de Chauny E, Metzger D, Pedicone G.
Read more > -
01/25/2011 One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: Investigation of neural correlates with BOLD MRI
Schunck T, Mathis A, Erb G, Namer IJ, Hode Y, Demazières A, Luthringer R.
Benzodiazepine effects on cholecystokinin tetrapeptide (CCK-4)-induced panic attack (PA) in humans are incompletely characterized, in particular on the neurofunctional level. This work explores the effects of lorazepam on brain activity and behavioral and physiological symptoms related to CCK-4-induced PA in healthy volunteers.
Read more > -
10/11/2010 Living alongside railway tracks: long-term effects of nocturnal noise on sleep and cardiovascular reactivity as a function of age.
Tassi P, Rohmer O, Schimchowitsch S, Eschenlauer A, Bonnefond A, Margiocchi F, Poisson F, Muzet A.
Very few studies were devoted to permanent effects of nocturnal railway noise on sleep and cardiovascular reactivity. We investigated the effects of nocturnal railway noise on sleep and cardiovascular response in young and middle-aged adults living for many years either near a railway track or in a quiet area. Read more > -
10/07/2010 Assessment of spontaneous and evoked gamma oscillations by quantified EEG, a potential biomarker of glutamatergic transmission : methodological issues in humans, descriptive data and test-retest reliability.
Luthringer R, Ferguson J, Boeijinga P, Pross N, Staner C. Soufflet L, Maurice D, Viardot G, Danjou P.
Read more > -
10/07/2010 Initial validation of a multiarray pain model optimizing the evaluation of analgesic drugs in healthy volunteers.
Danjou P, Demazières A, Mallet de Chauny E, Metzger D, Pedicone G, Goupil N, Luthringer R.
Read more > -
09/14/2010 Differential sleep EEG effects of sleep restriction versus temazepam in healthy subjects and patients with psychophysiological insomnia.
Staner L, Cornette F, Pross N, Trecherel C, Girard N, Mallet de Chauny E, Metzger D, Muzet A.
Read more > -
09/14/2010 Mood and REM sleep effects of a 6-day 4-h sleep restriction protocol in healthy female subjects.
Cornette F, Pross N, Trecherel C, Gardinier S, Mallet de Chauny E, Metzger D, Guinot C, Muzet A, Morizot F, Staner L.
Read more > -
08/28/2010 Comparison of AChE inhibition and 5-HT1A blockade in healthy young volunteers on a scopolamine-challenge model of cognitive impairment.
Parks V, Patat A, Plotka A, Raje S, Wesnes K, Boeijinga P.
Read more > -
07/22/2010 Usefulness of functional MRI
Kremer S, Nicolas-Ong C, Schunck T, Schenck M, Collange O, Mutschler V, Namer IJ, Dietemann JL, Delon-Martin C, Schneider F.
Read more > -
06/14/2010 Assessment of spontaneous and evoked gamma oscillations by quantified EEG, a potential biomarker of glutamatergic transmission : methodological issues in humans, descriptive data and test-retest reliability.
Luthringer R, Ferguson J, Boeijinga P, Pross N, Staner C. Soufflet L, Maurice D, Viardot G, Danjou P.
Read more > -
06/08/2010 Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.
Staner C, Joly F, Jacquot N, Vlasova ID, Nehlin M, Lundqvist T, Edenius C, Staner L.
OBJECTIVE: To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar*) 10 mg vs oral formulation (Ambien dagger ) 10 mg by polysomnography (PSG) in DSM-IV primary insomnia patients. Primary objective was to compare the two formulations on sleep induction, measured by latency to persistent sleep (LPS), sleep onset latency (SOL) and latency to stage 1 (ST1L).
Read more > -
06/05/2010 Phase I, randomized, double-blind, placebo-controlled, crossover study to compare the pharmacokinetics of a single oral dose of a new zaleplon formulation (SKP-1041) and open label zaleplon in healthy elderly subjects.
Greenblatt DJ, Danjou P, Luthringer R, Metzger D, Otmani S, Pross N, Osbakken M, McCormick A, Walsh J.
Read more > -
06/05/2010 Phase I, randomized, crossover study to compare day vs night pharmacokinetics of a single oral dose of a new zaleplon forumulation in healthy young volunteers.
Staner L, Luthringer R, Viardot G, Metzger D, Tisserant A, Osbakken M, McCormick A, Walsh JK, Greenblatt DJ.
Read more > -
05/19/2010 Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge.
Schunck T, Mathis A, Erb G, Namer IJ, Demazières A, Luthinger R.
Human models of anxiety are useful to develop new effective anxiolytics. The objective of this study was to use functional magnetic resonance imaging (fMRI) to test the hypothesis that a single dose of lorazepam modifies brain activation during an anxiety challenge. Read more > -
03/17/2010 Cardiovascular responses to railway noise during sleep in young and middle-aged adults.
Tassi P, Saremi M, Schimchowitsch S, Eschenlauer A, Rohmer O, Muzet A.
The aim of this study was to investigate the effects of nocturnal railway noise on cardiovascular reactivity in young (25.8 +/- 2.6 years) and middle-aged (52.2 +/- 2.5 years) adults during sleep. Read more > -
03/17/2010 Comparison of the post-nap versus first-night effect models of transient insomnia by means of visual and spectral sleep EEG analyses.
Cornette F, Metzger D, Muzet A, Luthringer R, Staner L.
Read more > -
03/17/2010 An electroencephalographic study with brain oscillatory recording to assess how benzodiazepines affect auditory versus visual cognitive processes.
Luthringer R, Muzet M, Boeijinga P.
Read more > -
02/12/2010 Comorbidity of insomnia and depression.
Staner L.
During the last decade, several studies have shown that insomnia, rather than a symptom of depression, could be a medical condition on its own, showing high comorbidity with depression. Epidemiological research indicates that insomnia could lead to depression and/or that common causalities underlie the two disorders. Read more > -
01/19/2010 Nelotanserin, a novel selective human 5-Hydroxytryptamine2A inverse agonist for the treatment of insomnia.
Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, Morgan M, Shanahan W, Teegarden BR, Thomsen WJ, Behan D.
5-Hydroxytryptamine (5-HT)(2A) receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance insomnias. Among these agents is nelotanserin, a potent, selective 5-HT(2A) inverse agonist.
Read more > -
10/23/2009 F-svc: a simple and fast training algorithm soft margin support vector classification.
Tohme M, Lengellé R.
Support vector machines have obtained much success in machine learning. But their training require to solve a quadratic optimization problem so that training time increases dramatically with the increase of the training set size. Read more > -
10/23/2009 Classification of psychotropic drugs in a high dimensional space: Some preliminary results on hypothesis stability and power function.
Tohme M, Lengellé R, Boeijinga P.
In this paper, we propose an approach to classify psychotropic drugs from the events related potential (ERP) signals using the P300 components. Read more > -
10/22/2009 [Insomnia caused by environmental factors]
Muzet A.
Several studies are interested in sleep disturbances caused by environmental conditions (noise, temperature…) because sleep is sensitive to theses factors which are often ignored and underestimated. Read more > -
10/14/2009 The effect of aging on the inhibitory function in middle-aged subjects: a functional MRI study coupled with a color-matched Stroop task.
Mathis A, Schunck T, Erb G, Namer IJ, Luthringer R.
OBJECTIVE: The effects of aging on the inhibitory function are largely described in the neuroimaging literature but little data is available on the beginning of this age-related impairment.
Read more > -
09/23/2009 Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
Luthringer R, Djupesland PG, Sheldrake CD, Flint A, Boeijinga P, Danjou P, Demazières A, Hewson G.
OBJECTIVES: The aim was to investigate the pharmacokinetics of intranasal sumatriptan (administered using a novel bi-directional powder delivery device) and study its effects on quantitative electroencephalography in patients with migraine. The safety profiles of the two formulations were also compared.
Read more > -
09/10/2009 Can Nose-to-Brain transport of anti-migraine drugs along the trigeminal nerve improve therapeutic effects while minimizing the risk of systemic adverse events?
Djupesland PG, Luthringer R, Docekal P.
Read more > -
09/02/2009 The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.
Luthringer R, Muzet M, Zisapel N, Staner L.
Objectives of this study were to investigate the effects of prolonged-release melatonin 2 mg (PRM) on sleep and subsequent daytime psychomotor performance in patients aged > or =55 years with primary insomnia, as defined by fourth revision of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association. Read more > -
08/24/2009 Sequential maximum gradient optimization for support vector detection.
Tohmé M, Lengellé R.
Read more > -
06/10/2009 Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.
Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T.
OX22 is zolpidem formulated for sublingual administration. The primary objective of the present study was to evaluate the efficacy of single doses of sublingual zolpidem (5 and 10mg) versus oral zolpidem (10mg), with regard to latency to persistent sleep (LPS), in a post-nap model of insomnia. Read more > -
06/06/2009 Relationship of subjective and objective endpoints for outcomes of a phase I trial of a potential new sleep agent.
Luthringer R, Pross N, Otmani S, Staner C, Staner L.
Read more > -
06/06/2009 Pharmacodynamic profile of three novel formulations of Zaleplon versus placebo and marketed Zaleplon measured by electroencephalography in healthy volunteers.
Otmani S, Soufflet L, Staner L, Luthringer R.
Read more > -
06/06/2009 Use of the addiction research center inventory (sedation subscale) and the Karolinska Sleepiness Scale to evaluate subjective alertness after single oral doses of Zaleplon in three novel formulations.
Pross N, Staner L, Luthringer R, Staner C.
Read more > -
06/06/2009 Effects of Eplivanserin, a non-sedative agent, on driving an cognitive/psychomotor performance a randomizes placebo-and active-controlled trial in insomnia patients with difficulties maintaining sleep.
Luthringer R, Floch A, Delfolie A, Nicolas O, Brunet A, Pinquier J (presented by Staner L).
Read more > -
06/06/2009 Pharmacokinetic profile of single oral doses of Zaleplon in three novel formulations in normal volunteers.
Gassen M, Kress A, Nedelec J, Francart C, Staner C.
Read more > -
06/06/2009 ITI-007 / ITI-722, A new Approach for the treatment of sleep maintenance insomnia and sleep disorders associated with psychiatric and neurological diseases.
Vanover K, Staner L, Luthringer R, Mates S, Davis R.
Read more > -
06/06/2009 Pharmacodynamic profile of three novel formulations of Zaleplon in normal volunteers as evaluated by the Multiple Sleep Latency Test.
Walsh J, Cornette F, Staner C, Tisserant A, Luthringer R, Staner L.
Read more > -
04/07/2009 Un sommeil perturbé: les répercussions d’une exposition répétée au bruit ambiant.
Muzet A.
Read more > -
04/04/2009 Reversal of « schizophrenia-like » and « dementia-like » MMN deficits induced by blockade of excitatory pathways in humans: effects of indirect nmda-modulators.
Boeijinga PH, Santoro F, Staner C.
Read more > -
03/06/2009 Effect of a short nap on the alertness of young drivers : Repercussion on the perception of motorcycles according to extent of the useful visual field of the driver.
Roge J, Otmani S, Bonnefond A, Depayle T, Muzet A.
The objectives of this study are to analyze the effect of a short nap on the level of alertness and on the drivers’ ability to detect the motorcyclists on the road according to the size of his/her useful visual field (UVF). Read more > -
03/01/2009 Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M.
Long-duration (> or = 6 months) polysomnographic studies of insomnia medications are lacking. This study evaluated the long-term efficacy of ramelteon, a selective MT1/MT2 melatonin-receptor agonist used for insomnia treatment. Read more > -
01/30/2009 Relationships between the number of ultradian cycles and key sleep variables in outpatients with major depressive disorder.
Le Bon O, Hoffmann R, Staner L, Armitage R.
The regulation of the alternation between rapid eye movement sleep (REMS) and non-rapid eye movement sleep (NREMS) is still a matter of much debate. It is also an important topic for psychiatric research, since both sleep components show anomalies in Major Depressive Disorders (MDD) and related syndromes. Read more > -
12/18/2008 [Sleep disturbance due to environnemental factors and their impact on everyday life].
Muzet A.
Sleep must be protected against aggressions and manipulations, made voluntarily or not, which tend to reduce its duration to the benefit of prolonged waking state. Sleep disturbances have various origins but only external factors of our environment, such as noise and extreme thermal ambient conditions, will be considered here. Read more > -
12/03/2008 Novel prepulse processing ERP paradigms as marker of experimentally induced psychodysleptic deteriorations : a 3 case studies of Ketamine effets on auditory N100-gating and its reversal in the human brain.
Boeijinga PH, Pross N, Luthringer R, Fattah S, Danjou P.
This paper deals with a new type of access to gating function in the brain, namely the comparison of the N100 auditory responses to an overt tone burst, and its inhibition when paired with a weak (i.e. auditory click but small in amplitude) prepulse.
Read more > -
12/01/2008 Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
Otmani S, Demazières A, Staner C, Jacob N, Nir T, Zisapel N, Staner L.
Melatonin is an important regulator of the sleep–wake cycle. A prolonged-release formulation of melatonin (PR-M) that essentially mimics the profile of the endogenous production of the hormone is effective in the treatment of insomnia in patients aged 55 years and older. Because hypnotics result in impairments of various cognitive skills, it is important to examine the cognitive effects associated with the use of PR-M.
Read more > -
09/24/2008 Classification of psychotropic drugs: validation of neurophysiological markers projected in a high dimensional space.
Tohme M, Lengellé R, Boeijinga PH.
Read more > -
09/24/2008 P300 differences in averaged event related potentials and event related oscillations: ketamine, apomorphine and the model for an endophenotype for schizophrenia.
Boeijinga PH, Soufflet L, Luthringer R.
Read more > -
09/09/2008 [Working memory development: Central executive’s relationships with the phonological loop and the visuospatial sketchpad in second and fifth grade children].
Pross N, Gaonac'h D, Gaux C.
The aim of this study was to examine the development of working memoryʼs components and their relationships. Phonological loopʼs, visuospatial sketchpadʼs and central executiveʼs efficiencies were assessed by simple and complex span tasks and executive tasks with verbal and visuospatial material. Read more > -
09/09/2008 Real-Time Automatic Measure of Drowsiness based on a Single EEG Channel.
Berthomier C, Muzet A, Berthomier P, Prado J, Mattout J.
Read more > -
09/01/2008 Severity of obstructive sleep apnoea/hypopnoea syndrome and subsequent waking EEG spectral power.
Grenèche J, Sarémi M, Erhardt C, Hoeft A, Eschenlauer A, Muzet A, Tassi P.
It is well known that most patients with obstructive sleep apnoea/hypopnoea syndrome (OSAHS) suffer sleepiness, although the underlying mechanisms of this relationship remain unclear. The present study examined the relationship between nocturnal variables and the subsequent waking electroencephalogram (EEG), in order to determine if sleepiness was related to OSAHS severity and due to sleep fragmentation or to nocturnal hypoxaemia. Read more > -
08/12/2008 Intranasal Sumatriptan powder delivered with a new device is as effective as 6 mg SC Sumatriptan in preventing glyceryltrinitrate (GTN) challenge induced EEG changes in migraineurs.
Luthringer R, Sheldrake CD, Flint A, Djupesland PG.
Read more > -
08/07/2008 Clinical study of VSF-173 in a model of excessive sleepiness.
Birznieks G, Feeney, J, Liv S, Baroldi P, Luthringer R, Staner L, Martzloff D, Polymeropoulos M.
Read more > -
07/11/2008 Are OSAS patients impaired in their driving ability on a circuit with medium traffic density?
Tassi P, Grenèche J, Pebayle T, Eschenlauer A, Hoeft A, Bonnefond A, Rohmer O, Muzet A.
Many studies have demonstrated that patients with Obstructive Sleep Apnea Syndrome (OSAS), a very common sleep-related breathing disorder, are usually impaired in their driving ability because of decreased sleep quality. However, most of the simulation procedures in laboratories are designed to create monotonic conditions with low traffic density, if any, thereby leading to a dramatic decrease in performance in OSAS patients because of the lack of stimulation. The aim of this study was therefore to evaluate driving abilities in OSAS patients involved in a driving simulation task with medium traffic density, in order to replicate as far as possible real world conditions. The behavioral and physiological attributes likely to predict driving performance in these patients were also investigated. Read more > -
05/05/2008 Effects of nocturnal railway noise on subsequent cognitive performance and subjective ratings.
Bonnefond A, Saremi M, Rohmer O, Hoeft A, Eschenlauer A, Eschenlauer R, Muzet A , Tassi P.
The present study intended to investigate the effects of nocturnal railway noise on the three components of attention (alertness, orientation and executive control), and on subjective ratings of sleep quality, fatigue, wellbeing and discomfort. Read more > -
03/31/2008 F-SVR: a new learning algorithm for support vector regression.
Tohmé M, Lengellé R.
In this paper, we present a new method for optimizing support vector machines for regression problems. This algorithm searches for efficient feasible directions. Within these selected directions, we choose the best one, i.e. the one, coupled with an optimal step analytical evaluation, that ensures a maximum increase of the objective function. Read more > -
03/30/2008 F-SVR: a new learning algorythm for support vector regression.
Tohme M, Lengellé R.
Read more > -
03/07/2008 Test-retest reliability of a functional MRI anticipatory anxiety paradigm in healthy volunteers.
Schunck T, Erb G, Mathis A, Jacob N, Gilles C, Namer IJ, Meier D, Luthringer R.
PURPOSE: To evaluate the reproducibility of neural activations induced by an anticipatory anxiety provocation challenge in healthy volunteers.
Read more > -
03/04/2008 The impact of age on useful visual field deterioration and risk evaluation in a simulated driving task.
Rogé J, Otmani S, Pébayle T, Muzet A.
The primary goal of this study is to evaluate whether the driver can estimate his performance and the deterioration of his state of alertness during a simulated driving task. The second goal is to study the relation between useful visual field (UVF) deterioration and the capacity to estimate performance in a visual task and the decrease of level of alertness as a function of age. Read more > -
02/07/2008 EEG spectral power and sleepiness during 24 h of sustained wakefulness in patients with obstructive sleep apnea syndrome.
Grenèche J, Krieger J, Erhardt C, Bonnefond A, Eschenlauer A, Muzet A, Tassi P.
This study investigated if obstructive sleep apnea syndrome (OSAS) may be associated with higher activity in different frequency bands of the EEG during a sustained wakefulness paradigm. Read more > -
12/13/2007 Abnormal functional integration in schizophrenia: fMRI and MEG imaging are pointing to the same issues.
Foucher J, Vidailhet P, Boeijinga PH, Hodé Y, Soufflet L , Pham BT, Danion JM.
Abstracted in Eur Arch Psychiatry Clin Neurosci 2007 ; 257 (suppl 2): 31-32.Â
Best Poster Award Read more > -
12/13/2007 P300 differences in averaged Event Related Potentials and Event Related Oscillations : ketamine, apomorphine and the model for an endophenotype for schizophrenia.
Boeijinga PH, Soufflet L, Luthringer R.
Read more > -
12/09/2007 Comparison of the effects of benzodiazepines on induced gamma activity in auditory and visual cognitive tasks.
Luthringer R, Boeijinga PH, Muzet M, Ferguson J.
Read more > -
11/15/2007 Short treatment with Gaboxadol improves sleep maintenace and enhances slow wave sleep in adult patients with primary insomnia.
Lundahl J, Staner L, Staner C, Loft H, Deacon S.
RATIONALE: Gaboxadol is a selective extrasynaptic GABA(A) agonist, previously in development for the treatment of insomniac patients.
OBJECTIVE: To evaluate the acute efficacy and safety of gaboxadol in primary insomnia (PI).
Read more > -
09/07/2007 A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended release tablets on sleep architecture in patients with schizophrenia.
Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Battisti WP, Palumbo JM.
The effects of paliperidone extended-release on sleep architecture in patients with schizophrenia-related insomnia were evaluated in this multicenter, double-blind, randomized, placebo-controlled study. Read more > -
08/22/2007 Insomnia treatment assessment based on physiological data analysis.
Chouvarda I, Papadelis C, Domis N, Staner L, Maglaveras N.
For the purposes of insomnia treatment, pharmacotherapy is widely used, despite the possibility for the use of behavioural treatment of insomnia. Thus, the assessment and treatment of patients with insomnia needs further investigation. This work addresses insomnia treatment evaluation and medication side-effect assessment based on continuous physiological signals such as EEG and ECG monitoring and analysis. Read more > -
08/14/2007 Psychotropic profile of S 17092, a prolyl-endopeptidase inhibitor, using quantitative EEG in young healthy volunteers.
Morain P, Boeijinga P, Demazières A, De Nanteuil G, Luthringer R.
The central activity of S 17092, a prolyl endopeptidase (PEP) inhibitor, was investigated by quantitative electroencephalography (qEEG) in 48 young healthy men participating in a double-blind, randomized, placebo-controlled, cross-over study. Read more > -
06/22/2007 Synchronization distinguishes drug effects on cognitive responses in visual modality from auditory ‘oddball’: human neuropharmacology of GABAergic transmission.
Boeijinga P.
Read more > -
06/11/2007 Brain nicotinic stimulation in healthy volunteers causes EEG changes which precede improvement in attention and episodic memory.
Boeijinga P, Dunbar G, Demazières A (presented by R. Luthringer).
Read more > -
05/19/2007 Attention inhibitory process decline during life span: a functional MRI study.
Mathis A.
Read more > -
05/16/2007 Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.
Dunbar G, Boeijinga PH, Demazières A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R.
OBJECTIVES: The aim of this study was to get insight into the central effects of TC-1734 (renamed AZD3480), a selective agonist at the neuronal nicotinic receptor of the alpha4beta2 subtype.
Read more > -
05/10/2007 Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man.
Boeijinga PH, Soufflet L, Santoro F, Luthringer R.
Disturbances in integrative function have been consistentLy described in psychotic disorder; for instance, prepulse inhibition of the startle reflex (startle-PPI) which is a marker of sensory gating, is deficient in persons with schizophrenia. The N-methyl-D-aspartate antagonist ketamine produces in control subjects a spectrum of neurobehavioural symptoms like encountered in schizophrenia, and disrupts startle-PPI in animals. Read more > -
05/02/2007 Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.
Gilles C, Luthringer R.
Animal models of diseases are widely used in the preclinical phase of drug development. They have a place in early human clinical psychopharmacology as well, in order to get early clues that contribute to establish the proof of concept (POC) already in healthy volunteers (HV). Read more > -
04/05/2007 Environmental noise, sleep and health.
Muzet A.
Unlike other physical ambient factors (i.e. electromagnetic fields or air pollutants), noise is perceived by a specific system (auditory system) in humans. It is therefore a phenomenon that is sensed and evaluated by everybody, and this is why exposure to noise is one of the most, if not the most, frequent complaints of populations living in large cities.
Read more > -
03/28/2007 Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets.
Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Palumbo J, Eerdekens M.
Read more > -
03/08/2007 Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia.
Deacon S, Staner L, Staner C, Legters A, Loft H, Lundahl J.
STUDY OBJECTIVE: To perform an early evaluation of the efficacy and safety of gaboxadol in the treatment of primary insomnia.
Read more > -
12/01/2006 Nonlinear regularized wiener filtering with kernel : application in denoising MEG data corrupted by ECG.
Constantin I, Richard C, Lengellé R, Soufflet L.
Magnetoencephalographic and electroencephalographic recordings are often contaminated by artifacts such as eye movements, blinks, and cardiac or muscle activity. These artifacts, whose amplitude may exceed that of brain signals, may severely interfere with the detection and analysis of events of interest. In this paper, we consider a nonlinear approach for cardiac artifacts removal from magnetoencephalographic data, based on Wiener filtering. Read more > -
11/27/2006 [The effects of noise on sleep and their possible repercussions on health].
Muzet A.
Sleep is a physiological recuperative state susceptible to be disturbed or reduced in length under external stimuli, such as noise, one of the most frequent ambient factors. Read more > -
09/01/2006 Effects of acamprosate on sleep during alcohol-withdrawal : a double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects.
Staner L, Boeijinga PH, Danel T, Gendre I, Muzet M, Landron F, Luthringer R.
Sleep disturbances are frequently encountered in alcohol-dependent patients. Drugs improving sleep during abstinence from alcohol may play an important role in the recovery process. In the present study, the effects of acamprosate, a drug successfully used in maintaining abstinence following alcohol withdrawal, were assessed by polysomnographic recordings. Read more > -
07/06/2006 Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers.
Dunbar G, Demazières A, Monreal A, Cisterni C, Metzger D, Kuchibhatla R, Luthringer R.
Recent research suggests that drugs activating nicotine acetylcholine receptors might be promising therapy in cognitive decline seen in the elderly, including Alzheimer's disease. Ispronicline (TC-1734), a brain-selective alpha4beta2 nicotine acetylcholine receptor partial agonist, has shown memory-enhancing properties in rodents and a good tolerability profile. Read more > -
07/01/2006 Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety.
Schunck T, Erb G, Mathis A, Gilles C, Namer IJ, Hode Y, Demazieres A, Luthringer R.
The main objective of this work was to study the functional markers of the clinical response to cholecystokinin tetrapeptide (CCK-4). Twelve healthy male subjects were challenged with CCK-4 and simultaneously underwent functional magnetic resonance imaging (fMRI) recording. Read more > -
06/14/2006 Catastrophe theory enables moves to be detected towards and away from self-organization: the example of epileptic seizure onset.
Cerf R.
Macroscopic systems with many interacting subunits, when driven far from equilibrium, exhibit self-organization, for example when a pathological rhythm appears suddenly in an epileptic patient. Sudden changes occurring while conditions vary smoothly have, in cases of interest, underlying mathematics that are the subject of Thom's catastrophe theory. Read more > -
04/05/2006 Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep.
Aubin HJ, Luthringer R, Demazières A, Dupont C, Lagrue G.
Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep.
Read more > -
03/22/2006 Ability of a new oral nicotine substitute to reduce smoking urge in moderate smokers.
Demazieres A, Luthringer R, Coppel E, Gilles C, Fleury C, Roegel JC, Delarue A, Laur C, Lagrue G.
Ability of a new oral nicotine substitute to reduce smoking urge in moderate smokers.
Read more > -
03/01/2006 Surrogate outcomes in neurology, psychiatry, and psychopharmacology.
Staner L.
A surrogate outcome can be defined as an outcome that can be observed sooner, at lower cost, or less invasively than the true outcome, and that enables valid inferences about the effect of intervention on the true outcome. There is increasing interest in the use of surrogate outcomes of treatment efficacy measurement in investigational drug trials. However, the significance of surrogate markers of treatment outcome in neurology and psychiatry has not yet been sufficiently demonstrated Read more > -
03/01/2006 Sleep effects of a 24-hour versus a 16-hour nicotine patch: a polysomnographic study during smoking cessation.
Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G.
Sleep disturbance is a common symptom of tobacco withdrawal and might contribute to early relapse vulnerability in abstinent smokers. This study was designed to compare the effects on sleep of nicotine patches applied either for 24 h (Nicopatch) or 16 h (Nicorette). Read more >